Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $93.33 Consensus PT from Analysts

Key Points

• The consensus rating for Prestige Consumer Healthcare Inc. (NYSE: PBH) is a "Moderate Buy", with three analysts recommending a hold and three a buy.
• The company's recent earnings report showed an EPS of $0.95, missing analysts' expectations, with revenue down 6.6% year-over-year.
• Institutional ownership is high, with 99.95% of shares held by institutional investors, indicating strong institutional interest in the stock.

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $93.3333.

A number of analysts recently issued reports on PBH shares. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Finally, Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research report on Friday, August 8th.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Large investors have recently made changes to their positions in the company. Bank of Montreal Can raised its position in shares of Prestige Consumer Healthcare by 15.1% in the fourth quarter. Bank of Montreal Can now owns 7,127 shares of the company's stock valued at $557,000 after buying an additional 937 shares in the last quarter. Sterling Capital Management LLC raised its position in shares of Prestige Consumer Healthcare by 837.1% in the fourth quarter. Sterling Capital Management LLC now owns 1,593 shares of the company's stock valued at $124,000 after buying an additional 1,423 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Prestige Consumer Healthcare by 4.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,182 shares of the company's stock valued at $405,000 after buying an additional 211 shares in the last quarter. Barclays PLC raised its position in shares of Prestige Consumer Healthcare by 20.8% in the fourth quarter. Barclays PLC now owns 111,689 shares of the company's stock valued at $8,721,000 after buying an additional 19,245 shares in the last quarter. Finally, Mariner LLC raised its position in shares of Prestige Consumer Healthcare by 12.6% in the fourth quarter. Mariner LLC now owns 5,492 shares of the company's stock valued at $429,000 after buying an additional 615 shares in the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 0.3%

Prestige Consumer Healthcare stock traded down $0.1860 during mid-day trading on Friday, hitting $65.2240. 657,471 shares of the company's stock were exchanged, compared to its average volume of 549,104. The firm has a market capitalization of $3.21 billion, a P/E ratio of 15.31, a PEG ratio of 2.07 and a beta of 0.43. Prestige Consumer Healthcare has a fifty-two week low of $62.95 and a fifty-two week high of $90.04. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The company's 50 day simple moving average is $76.03 and its 200-day simple moving average is $81.31.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. During the same period in the prior year, the business earned $0.90 EPS. The business's revenue for the quarter was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, equities analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.